Based on our and other results, incorporation of NF-κB inhibitors, such as small molecules targeting the IKK complex or other indirect NF-κB inhibitors (i.e. PARP inhibitors), should be considered to avoid the expression of genes involved in chemoresistance and relapse and, thus improving the clinical benefit and the outcome of breast cancer patients. The gene discussed is NFKB1; the disease is breast carcinoma.